Research on the clinical significance of CTHRC1 for HBV

doi:10.3969/j.issn.1673-8640.2015.11.011

Abstract

Abstract: Objective

To investigate the influence of hepatitis B virus(HBV) on the expression of collagen triple helix repeat containing 1(CTHRC1) and its clinical significance.

Methods

The mRNA and protein levels of CTHRC1 in HepG2 and HepG2.2.15 cells were determined by real-time reverse transcription polymerase chain reaction (PCR). Serum CTHRC1 levels were measured by enzyme-linked immunosorbent assay (ELISA), and the differences of serum CTHRC1 levels among healthy subjects without HBV infection(control group), asymptomatic HBV carriers, patients with chronic hepatitis B, patients with hepatic fibrosis induced by HBV infection and patients with HBV-related hepatocellular carcinoma (HCC) were analyzed.

Results

The expression of CTHRC1 mRNA was higher in HepG2.2.15 cells than in HepG2 cells, serum CTHRC1 levels were much higher in asymptomatic HBV carriers than in control group (P < 0.05), and CTHRC1 was detected at higher levels in patients with HBV-related group HCC than in those with hepatic fibrosis induced by HBV infection and chronic hepatitis B (P < 0.05).

Conclusions

HBV can upregulate the expression of CTHRC1, which is associated with the progression of HBV infection.

Key words: Collagen triple helix repeat containing 1, Hepatitis B virus, Hepatic fibrosis, Hepatocellular carcinoma

CLC Number:

R446.62

SONG Hui, LIU Xinghui, SHEN Zhenhua, CHEN Qing, XU Fengxia, XU Limin. Research on the clinical significance of CTHRC1 for HBV[J]. Laboratory Medicine, 2015, 30(11): 1104-1106.

Figures/Tables 4

References 10

[1]	WANG FS, FAN JG, ZHANG Z, et al.The global burden of liver disease: the major impact of China[J]. Hepatology, 2014, 60(6): 2099-2108.
[2]	KE Z, HE W, LAI Y, et al.Overexpression of collagen triple helix repeat containing 1 (CTHRC1) is associated with tumour aggressiveness and poor prognosis in human non-small cell lung cancer[J]. Oncotarget, 2014, 5(19):9410-9424.
[3]	CHEN YL, WANG TH, HSU HC, et al.Overexpression of CTHRC1 in hepatocellular carcinoma promotes tumor invasion and predicts poor prognosis[J]. PLoS One, 2013, 8(7):e70324.
[4]	TAN F, LIU F, LIU H, et al.CTHRC1 is associated with peritoneal carcinomatosis in colorectal cancer: a new predictor for prognosis[J]. Med Oncol, 2013, 30(1):473.
[5]	PARK EH, KIM S, JO JY, et al.Collagen triple helix repeat containing-1 promotes pancreatic cancer progression by regulating migration and adhesion of tumor cells[J]. Carcinogenesis, 2013, 34(3): 694-702.
[6]	TAKESHITA S, FUMOTO T, MATSUOKA K, et al.Osteoclast-secreted CTHRC1 in the coupling of bone resorption to formation[J]. J Clin Invest, 2013, 123(9):3914-3924.
[7]	KIM HC, KIM YS, OH HW, et al.Collagen triple helix repeat containing 1 (CTHRC1) acts via ERK-dependent induction of MMP9 to promote invasion of colorectal cancer cells[J]. Oncotarget, 2014, 5(2):519-529.
[8]	PITULE P, VYCITAL O, BRUHA J, et al.Differential expression and prognostic role of selected genes in colorectal cancer patients[J]. Anticancer Res, 2013, 33(11): 4855-4865.
[9]	TANG SC, CHEN YC.Novel therapeutic targets for pancreatic cancer[J]. World J Gastroenterol, 2014, 20(31):10825-10844.
[10]	TAMEDA M, SUGIMOTO K, SHIRAKI K, et al.Collagen triple helix repeat containing 1 is overexpressed in hepatocellular carcinoma and promotes cell proliferation and motility[J]. Int J Oncol, 2014 , 45(2):541-548.

[1]	Clinical Laboratory Society of Chinese Association for Rehabilitation Medicine , Molecular Diagnostics Society of Shanghai Medical Association , Tumor Immunology Branch of Shanghai Society for Immunology , Yueyang Hospital of Integrated Traditional Chinese and Western Medicine of Shanghai University of Traditional Chinese Medicine , Shanghai Center for Clinical Laboratory, Clinical Laboratory Society of Chinese Association of Integrative Medicine , Clinical Laboratory Society of Shanghai Anticancer Association , Tumor Markers Society of Shanghai Anticancer Association . Expert consensus on the clinical application of AFP，AFP-L3% and DCP using GALAD and GALAD-like models in hepatocellular carcinoma [J]. Laboratory Medicine, 2023, 38(7): 607-623.
[2]	CHEN Wenju, ZHOU Yong, XU Jiajia, WANG Pan. Role of serum exosomal miR-23b-3p and miR-4429 in patients with hepatocellular carcinoma [J]. Laboratory Medicine, 2023, 38(7): 624-628.
[3]	ZHANG Ying, JING Lijuan, LI Li. Relationship between the expression of miR-138 in peripheral blood mononuclear cells of hepatitis B virus proliferation in carriers [J]. Laboratory Medicine, 2023, 38(6): 559-562.
[4]	LIU Yang, GENG Kunjing, LI Hongjiang, SHI Haoxi, CHEN Sisi. Relationship of 25（OH）D₃ and liver inflammatory stage with the efficacy of antiviral therapy [J]. Laboratory Medicine, 2022, 37(7): 628-631.
[5]	MENG Jun, WANG Junqing, FEI Xiaochun, GU Zhidong. Establishment and validation of a plasma exosome-derived circular RNA model for HCC diagnosis [J]. Laboratory Medicine, 2022, 37(1): 1-10.
[6]	MA Yanting, SU Xi, HUANG Fei, WANG Mengxian, SHEN Minna, ZHANG Chunyan, WANG Beili, PAN Baishen, GUO Wei. Clinical role of HBV RNA detection in chronic hepatitis B [J]. Laboratory Medicine, 2022, 37(1): 72-77.
[7]	LI Caidong, ZHANG Xuqiang, LEI Zhiping, CHEN Qiaoli, CHEN Lu, TIAN Pengfei, DUAN Zhengjun. Clinical values of IL-1β,IL-6 and TNF-α in different clinical courses of chronic HBV infection [J]. Laboratory Medicine, 2021, 36(8): 790-794.
[8]	LIU Tingting, LIN Yuting, Mila , LI Xiaoqin. Correlation between serum IL-33 level and its gene polymorphism and the clinical outcome of HBV infection [J]. Laboratory Medicine, 2021, 36(11): 1101-1105.
[9]	SONG Hui, YANG Lan, XU Limin, SHEN Zhenhua, LIU Qianqian, LIU Xinghui. Influence and mechanism of hepatitis B virus on the expression of HOXA10 [J]. Laboratory Medicine, 2021, 36(11): 1172-1176.
[10]	TONG Lin, HUANG Chenjun, GAO Zhiyuan, ZHOU Jun, FANG Meng, XIAO Xiao, HE Yutong, HONG Song, XU Minfan, ZHU Feifei, GAO Chunfang. Study on the judgment model of preoperative microvascular invasion in HCC based on common clinical determination items [J]. Laboratory Medicine, 2020, 35(8): 741-748.
[11]	YUAN Yongming, ZHANG Xiaoying, GU Chao, ZHANG Jue, SUN Xuehua. Analysis of hepatitis B virus S protein mutation in chronic hepatitis B and cirrhosis patients [J]. Laboratory Medicine, 2020, 35(5): 428-433.
[12]	JIN Fangfang, JIN Zizheng, LIU Ning, LOU Jinli. Changes of CD3^bright T lymphocytes in patients with hepatocellular carcinoma before and after recurrence [J]. Laboratory Medicine, 2020, 35(3): 209-213.
[13]	BIE Lihan, FANG Meng, FENG Huijuan, LU Zhicheng, GAO Chunfang. Role of sialylated haptoglobin for the auxiliary diagnosis of hepatitis B-related hepatocellular carcinoma [J]. Laboratory Medicine, 2020, 35(11): 1147-1152.
[14]	GUAN Wenqian, GAO Zhiyuan, FENG Huijuan, HONG Song, HE Yutong, HE Lu, GAO Chunfang. Establishment of Lectin-ELISA for the detection of multi-antennary AAG and its preliminary application [J]. Laboratory Medicine, 2020, 35(11): 1177-1185.
[15]	LIU Yang, ZHANG Zhiping, PENG Daorong, SONG Liuwei, GE Shengxiang, HAO Xiaoke, LIU Jiayun. Establishment and performance evaluation of chemiluminescent microparticle immunoassay for the determination of high concentration HbsAg [J]. Laboratory Medicine, 2020, 35(10): 1056-1061.